Hims & Hers Health (HIMS) stock has surged 130% year-to-date, making it one of the standout names in digital health. Yet despite the rally, HIMS stock has slid more than 16% since late July, raising questions about whether the rally can last. While some analysts see the recent dip as a pause after strong gains, others stay bullish, citing Hims’ expanding growth in telehealth and weight-loss treatments as key long-term drivers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Canaccord Genuity Stays Positive
Canaccord Genuity analyst Maria Ripps kept a Buy rating and $68 price target on HIMS. The 5-star analyst said the stock’s recent weakness comes from short-term worries rather than structural issues. Ripps explained that shifting sexual health subscribers from on-demand orders to daily plans will slow growth for a few quarters. However, this change makes the subscriber base more loyal, sets up easier comparisons in 2026, and reflects management’s ability to add and scale new treatments.
She also highlighted that recent FDA guidance, along with a court decision dismissing Eli Lilly’s (LLY) lawsuit against Willow Health for selling copycat versions of its GLP-1 drugs, adds support to Hims’ GLP-1 business. Ripps believes Hims has several ways to grow, such as new care areas, expansion overseas, and compounded GLP-1 products. These could help the company meet its 2030 targets through several potential paths.
BTIG Stays Bullish on GLP-1 Growth
Meanwhile, BTIG analyst David Larsen kept a Buy rating and set a Street-high $85 target on Hims, indicating 53% upside potential. He said the revenue slowdown in Q2 was due to the end of the bulk compounding grace period in May 2025. Still, he expects sales from 503A compounded products to rise in the second half of the year.
Larsen also thinks Hims’ forecast of about $725 million in 2025 weight-loss revenue is conservative, and believes actual sales will be much higher. He remains confident that GLP-1 growth will pick up again and sees more upside for the stock.
Is HIMS a Good Stock to Buy?
Overall, Wall Street is sidelined on Hims & Hers Health stock, with a Hold consensus rating based on seven Holds, two Buys, and two Sells. The average HIMS stock price target of $49.00 indicates 11.71% downside potential.
